CoChat

Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release

Open access
Trivedi, Madhukar H., Dunner, David L., Kornstein, Susan G., Thase, Michael E., Zajecka, John M., Rothschild, Anthony J., Friedman, Edward S., Shelton, Richard C., Keller, Martin B., Kocsis, James H., Gelenberg, Alan · 2010 · Journal of Affective Disorders
Cited by 36

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background Psychosocial outcomes from the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated. Methods Adult outpatients with recurrent major depressive disorder (MDD) and response or remission following 6-month continuation treatment with venlafaxine extended release (ER) were randomized to receive venlafaxine ER or placebo for 1 year. Patients without recurrence on venlafaxine ER during year 1 were randomized to venlafaxine ER or placebo for year 2. Psychosocial functioning was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form (Q-LES-Q), Life EnjoymentScale—Short Version (LES-S), Social Adjustment Scale—Self-Report (SAS-SR) total and individual factors, Short Form Health Survey (SF-36) (vitality, social functioning, and role function-emotional items), and Longitudinal Interval Follow-up Evaluation (LIFE). Results At year 1 end, better overall psychosocial functioning was seen among patients randomly assigned to venlafaxine ER (n=129) vs placebo (n=129), with significant differences at end point on SF-36 role function-emotional, Q-LES-Q, and SAS-SR total, and work, house work, social/leisure, and extended-family factor scores (p≤0.05). At year 2 end, significant differences favored venlafaxine ER (n=43) vs placebo (n=40)on SF-36 vitality and rolefunction-emotional, Q-LES-Q, LES-S, LIFE, and SAS-SR total, social/leisure, and extended-family factor scores (p≤0.05). Limitations Patients with chronic MDD or treatment resistance were excluded and long-term specialist care was a financial incentive for treatment compliance. Discontinuation-related adverse events may have compromised the integrity of the treatment blind. Conclusions For patients with recurrent MDD, 2 years’ maintenance therapy with venlafaxine ER may improve psychosocial functioning vs placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jad.2010.04.011

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 25

  1. Daly, 2010, Health related quality of life in depression: a STAR*D report, Ann. Clin. Psychiatry, 22, 43, 10.1177/104012371002200107 · DOI · Paper page
  2. Endicott, 1993, Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure, Psychopharmacol. Bull., 29, 321
  3. Fawcett, 1983, Assessing anhedonia in psychiatric patients, Arch. Gen. Psychiatry, 40, 79, 10.1001/archpsyc.1983.01790010081010 · DOI · Paper page
  4. Hamilton, 1960, A rating scale for depression, J. Neurol. Neurosurg. Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  5. Jarrett, 2001, Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial, Arch. Gen. Psychiatry, 58, 381, 10.1001/archpsyc.58.4.381 · DOI · Paper page
  6. Judd, 2000, Psychosocial disability during the long-term course of unipolar major depressive disorder, Arch. Gen. Psychiatry, 57, 375, 10.1001/archpsyc.57.4.375 · DOI · Paper page
  7. Keitner, 1995, Role of the family in recovery and major depression, Am. J. Psychiatry, 152, 1002, 10.1176/ajp.152.7.1002 · DOI · Paper page
  8. Keller, 2007, The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two years (PREVENT) study: outcomes from the acute and continuation phases, Biol. Psychiatry, 62, 1371, 10.1016/j.biopsych.2007.04.040 · DOI
  9. Kennedy, 2007, Long-term social functioning after depression treated by psychiatrists: a review, Bipolar Disord., 9, 25, 10.1111/j.1399-5618.2007.00326.x · DOI · Paper page
  10. Kessler, 2003, The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R), JAMA, 289, 3095, 10.1001/jama.289.23.3095 · DOI · Paper page
  11. Kocsis, 2002, Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo, Arch. Gen. Psychiatry, 59, 723, 10.1001/archpsyc.59.8.723 · DOI · Paper page
  12. Kornstein, 2006, Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study, CNS Spectr., 10.1017/S1092852900015236 · DOI
  13. Lenze, 2002, Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: effects on social adjustment, Am. J. Psychiatry, 159, 466, 10.1176/appi.ajp.159.3.466 · DOI
  14. McHorney, 1994, Comparisons of the costs and quality of norms for the SF-36 health survey collected by mail versus telephone interview: results from a national survey, Med. Care, 32, 551, 10.1097/00005650-199406000-00002 · DOI · Paper page
  15. Miller, 1998, The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine, J. Clin. Psychiatry, 59, 608, 10.4088/JCP.v59n1108 · DOI · Paper page
  16. Papakostas, 2004, Psychosocial functioning during the treatment of major depressive disorder with fluoxetine, J. Clin. Psychopharmacol., 24, 507, 10.1097/01.jcp.0000138761.85363.d5 · DOI · Paper page
  17. Pettit, 2009, The long-term course of depression: development of an empirical index and identification of early adult outcomes, Psychol. Med., 39, 403, 10.1017/S0033291708003851 · DOI · Paper page
  18. Schechter, 2007, Quality of life of ‘normal’ controls: association with lifetime history of mental illness, Psychiatry Res., 152, 45, 10.1016/j.psychres.2006.09.008 · DOI
  19. Solomon, 2004, Psychosocial impairment and recurrence of major depression, Compr. Psychiatry, 45, 423, 10.1016/j.comppsych.2004.07.002 · DOI
  20. Trivedi, 2001, Sensitizing clinicians and patients to the social and functional aspects of remission, J. Clin. Psychiatry, 62, 32
  21. Trivedi, 2006, Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report, J. Clin. Psychiatry, 67, 185, 10.4088/JCP.v67n0203 · DOI · Paper page
  22. Trivedi, 2008, REVAMP—research evaluating the value of augmenting medication with psychotherapy: rationale and design, Psychopharmacol. Bull., 41, 5
  23. Vittengl, 2009, Deterioration in psychosocial functioning predicts relapse/recurrence after cognitive therapy for depression, J. Affect. Disord., 112, 135, 10.1016/j.jad.2008.04.004 · DOI
  24. Ware, 1996, A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity, Med. Care, 34, 220, 10.1097/00005650-199603000-00003 · DOI · Paper page
  25. Wisniewski, 2007, Comparison of quality of life measures in a depressed population, J. Nerv. Ment. Dis., 195, 219, 10.1097/01.nmd.0000258229.38212.6f · DOI

Cited by

Metadata

Authors
Trivedi, M. H., Dunner, D. L., Kornstein, S. G., Thase, M. E., Zajecka, J. M., Rothschild, A. J., Friedman, E. S., Shelton, R. C., Keller, M. B., Kocsis, J. H., & Gelenberg, A.
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2010-11
Volume
126
Issue
3
Pages
420-429
ISSN
0165-0327 (ISSN-L)
OpenAlex
W2127790797
Cited by
36
References
10
FWCI
1.43
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.